Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00233441 · ClinicalTrials.gov registry record · Phase 2

Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter

A Phase 2 study of Atrial Fibrillation and Atrial Flutter, sponsored by Sanofi.

Completed
Registry status
Phase 2
Development phase
673
Enrollment target
17
Study locations

NCT00233441 is a Phase 2 study of Atrial Fibrillation and Atrial Flutter that has completed, run by Sanofi. The registered enrollment target is 673 participants, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (78% lower). The trial reports 17 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00233441, a Phase 2 study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 2
Development phase
673 participants
Enrollment target
17
Study locations

Study Summary

Double blind study to evaluate the efficacy and tolerability of SSR149744C and select a dose to be further investigated in the maintenance of sinus rhythm after electrical, pharmacological or spontaneous conversion of AF/AFL.

Conditions Studied

Atrial Fibrillation Atrial Flutter

Interventions

  • DRUG CELIVARONE (SSR149744C)

Study Locations (17)

Other

  • Sanofi-Aventis Administrative Office - Buenos Aires
  • Sanofi-Aventis Administrative Office - Laval
  • Sanofi-Aventis Administrative Office - Santiago
  • Sanofi-Aventis Administrative Office - Hørsholm
  • Sanofi-Aventis Administrative Office - Paris
  • Sanofi-Aventis Administrative Office - Berlin
  • Sanofi-Aventis Administrative Office - Budapest
  • Sanofi-Aventis Administrative Office - Milan
  • Sanofi-Aventis Administrative Office - Tokyo
  • Sanofi-Aventis Administrative Office - Gouda
  • Sanofi-Aventis Administrative Office - Warsaw
  • Sanofi-Aventis Administrative Office - Moscow
  • Sanofi-Aventis Administrative Office - Barcelona
  • Sanofi-Aventis Administrative Office - Bromma
  • Sanofi-Aventis Administrative Office - Geneva

New Jersey

  • Sanofi-Aventis Administrative Office - Bridgewater

New South Wales

  • sanofi-aventis Australia & New Zealand administrative office - Macquarie Park

Trial Details

FieldValue
Enrollment Target 673 participants
Start Date 2004-12
Est. Completion 2006-05
Phase Phase 2

Sponsor

Sanofi

713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00233441

The ClinicalTrials.gov registry entry for NCT00233441 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 673 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (78% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which CELIVARONE (SSR149744C) is the first listed.

NCT00233441 reports 17 study locations spanning 3 distinct geographic areas - top geographies include Other, New Jersey, New South Wales.

Frequently Asked Questions

What is clinical trial NCT00233441 about?

NCT00233441 is a clinical study titled "Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter". Double blind study to evaluate the efficacy and tolerability of SSR149744C and select a dose to be further investigated in the maintenance of sinus rhythm after electrical, pharmacological or spontaneous conversion of AF/AFL.

What is the current status of trial NCT00233441?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 673 participants. The study started on 2004-12. Estimated completion is 2006-05.

What conditions does trial NCT00233441 study?

This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.

What interventions are being tested in trial NCT00233441?

The interventions under investigation include: CELIVARONE (SSR149744C) (DRUG).

Who is sponsoring clinical trial NCT00233441?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00233441 being conducted?

This trial has 17 study locations across New Jersey, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation

All registered trials for this condition

Atrial Flutter

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.